HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
tigemonam
structure given in first source
Also Known As:
SQ 30836; SQ-30836; Acetic acid, (((1-(2-amino-4-thiazolyl)-2-((2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-, (S-(Z))-
Networked:
5
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amides: 2428
Lactams: 2198
beta-Lactams: 2386
Monobactams: 118
tigemonam: 5
Sulfur Compounds: 278
beta-Lactams: 2386
Monobactams: 118
tigemonam: 5
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Lactams: 2198
Monobactams: 118
tigemonam: 5
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
beta-Lactams: 2386
Monobactams: 118
tigemonam: 5
Related Diseases
1.
Infections
09/01/1988 - "
It is concluded that tigemonam is a candidate for clinical trials in patients with infections caused by Gram-negative aerobes other than pseudomonas and acinetobacter.
"
02/01/1987 - "
In localized infections, tigemonam also demonstrated excellent in vivo activity.
"
02/01/1987 - "
In a variety of gram-negative systemic infections in mice, orally administered tigemonam was efficacious in all infections studied.
"
02/01/1989 - "
Tigemonam may have a valuable role in the management of infection caused by enterobacteria, particularly if bioavailability following oral administration is confirmed in human subjects.
"
2.
Community-Acquired Infections
05/01/1989 - "
It is concluded that tigemonam should play an important role in the treatment of nosocomial infections that do not require parenteral therapy and in the treatment of multiresistant community-acquired infections.
"
05/01/1989 - "
It is concluded that tigemonam should play an important role in the treatment of nosocomial infections that do not require parenteral therapy and in the treatment of multiresistant community-acquired infections.
"
3.
Cross Infection (Nosocomial Infection)
05/01/1989 - "
It is concluded that tigemonam should play an important role in the treatment of nosocomial infections that do not require parenteral therapy and in the treatment of multiresistant community-acquired infections.
"
05/01/1989 - "
It is concluded that tigemonam should play an important role in the treatment of nosocomial infections that do not require parenteral therapy and in the treatment of multiresistant community-acquired infections.
"
4.
Pyelonephritis
02/01/1987 - "
In acute pyelonephritis in mice caused by Escherichia coli or Proteus sp., tigemonam was very effective.
"
Related Therapies and Procedures
1.
Therapeutics
2.
Oral Administration